Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer

被引：75

作者：

Oliveira, Kelly C. S. ^{[1
]}

Ramos, Iago Barroso ^{[2
]}

Silva, Jessica M. C. ^{[1
]}

Barra, Williams Fernandes ^{[1
]}

Riggins, Gregory J. ^{[3
]}

Palande, Vikrant ^{[4
]}

Pinho, Catarina Torres ^{[1
]}

Frenkel-Morgenstern, Milana ^{[4
]}

Santos, Sidney E. B. ^{[1
]}

Assumpcao, Paulo P. ^{[1
]}

Burbano, Rommel R. ^{[5
]}

Calcagno, Danielle Queiroz ^{[1
]}

机构：

[1] Univ Fed Para, Nucleo Pesquisas Oncol, Belem, Para, Brazil

[2] Univ Fed Para, Programa Residencia Multiprofiss Saude, Hosp Univ Joao Barros Barreto, Belem, Para, Brazil

[3] Johns Hopkins Med, Brain Canc Biol & Therapy Res Lab, Baltimore, MD USA

[4] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel

[5] Hosp Ophir Loyola, Lab Biol Mol, Belem, Para, Brazil

来源：

MOLECULAR CANCER RESEARCH | 2020年 / 18卷 / 04期

关键词：

CELL-FREE DNA; ACQUIRED-RESISTANCE; TREATMENT RESPONSE; SYSTEMIC THERAPY; LIQUID BIOPSIES; ESR1; MUTATIONS; PLASMA DNA; GENE; IDENTIFICATION; IMMUNOTHERAPY;

D O I：

10.1158/1541-7786.MCR-19-0768

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive "liquid biopsy" tool in precision medicine. ctDNA-genomic DNA fragments that are released into the bloodstream after the active secretion of microvesicles or tumor cell lysis reflects tumor evolution and the genomic alterations present in primary and/or metastatic tumors. Notably, ctDNA analysis might allow the stratification of patients, the monitoring of the therapeutic response, and the establishment of an opportunity for early intervention independent of detection by imaging modalities or clinical symptoms. As oncology moves towards precision medicine, the information in ctDNA provides a means for the individual management of the patient based on their tumor's genetic profile. This review presents current evidence on the potential role for ctDNA in helping to guide individualized clinical treatment decisions for patients with melanoma, castration-resistant prostate cancer, breast cancer, metastatic colorectal cancer, and non-small cell lung cancer.

引用

页码：517 / 528

页数：12

共 92 条

[71] Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment [J].

Thierry, A. R. ;

El Messaoudi, S. ;

Mollevi, C. ;

Raoul, J. L. ;

Guimbaud, R. ;

Pezet, D. ;

Artru, P. ;

Assenat, E. ;

Borg, C. ;

Mathonnet, M. ;

De La Fouchardiere, C. ;

Bouche, O. ;

Gavoille, C. ;

Fiess, C. ;

Auzemery, B. ;

Meddeb, R. ;

Lopez-Crapez, E. ;

Sanchez, C. ;

Pastor, B. ;

Ychou, M. .

ANNALS OF ONCOLOGY, 2017, 28 (09) :2149-2159

[72] Origins, structures, and functions of circulating DNA in oncology [J].

Thierry, A. R. ;

El Messaoudi, S. ;

Gahan, P. B. ;

Anker, P. ;

Stroun, M. .

CANCER AND METASTASIS REVIEWS, 2016, 35 (03) :347-376

[73] Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA [J].

Thierry, Alain R. ;

Mouliere, Florent ;

El Messaoudi, Safia ;

Mollevi, Caroline ;

Lopez-Crapez, Evelyne ;

Rolet, Fanny ;

Gillet, Brigitte ;

Gongora, Celine ;

Dechelotte, Pierre ;

Robert, Bruno ;

Del Rio, Maguy ;

Lamy, Pierre-Jean ;

Bibeau, Frederic ;

Nouaille, Michelle ;

Loriot, Virginie ;

Jarrousse, Anne-Sophie ;

Molina, Franck ;

Mathonnet, Muriel ;

Pezet, Denis ;

Ychou, Marc .

NATURE MEDICINE, 2014, 20 (04) :430-+

[74] ESR1 ligand-binding domain mutations in hormone-resistant breast cancer [J].

Toy, Weiyi ;

Shen, Yang ;

Won, Helen ;

Green, Bradley ;

Sakr, Rita A. ;

Will, Marie ;

Li, Zhiqiang ;

Gala, Kinisha ;

Fanning, Sean ;

King, Tari A. ;

Hudis, Clifford ;

Chen, David ;

Taran, Tetiana ;

Hortobagyi, Gabriel ;

Greene, Geoffrey ;

Berger, Michael ;

Baselga, Jose ;

Chandarlapaty, Sarat .

NATURE GENETICS, 2013, 45 (12) :1439-U189

[75] Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment [J].

Uchibori, Ken ;

Inase, Naohiko ;

Nishio, Makoto ;

Fujita, Naoya ;

Katayama, Ryohei .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) :915-925

[76]

Uchoa Guimaraes Camila Tavares, 2018, Oncotarget, V9, P15144, DOI 10.18632/oncotarget.24540

[77] POINT MUTATIONS OF THE N-RAS GENE IN THE BLOOD-PLASMA DNA OF PATIENTS WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOGENOUS LEUKEMIA [J].

VASIOUKHIN, V ;

ANKER, P ;

MAURICE, P ;

LYAUTEY, J ;

LEDERREY, C ;

STROUN, M .

BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (04) :774-779

[78] Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients [J].

Vidal, J. ;

Muinelo, L. ;

Dalmases, A. ;

Jones, F. ;

Edelstein, D. ;

Iglesias, M. ;

Orrillo, M. ;

Abalo, A. ;

Rodriguez, C. ;

Brozos, E. ;

Vidal, Y. ;

Candamio, S. ;

Vazquez, F. ;

Ruiz, J. ;

Guix, M. ;

Visa, L. ;

Sikri, V. ;

Albanell, J. ;

Bellosillo, B. ;

Lopez, R. ;

Montagut, C. .

ANNALS OF ONCOLOGY, 2017, 28 (06) :1325-1332

[79] Liquid biopsies come of age: towards implementation of circulating tumour DNA [J].

Wan, Jonathan C. M. ;

Massie, Charles ;

Garcia-Corbacho, Javier ;

Mouliere, Florent ;

Brenton, James D. ;

Caldas, Carlos ;

Pacey, Simon ;

Baird, Richard ;

Rosenfeld, Nitzan .

NATURE REVIEWS CANCER, 2017, 17 (04) :223-238

[80]

Wang Victoria, 2017, J Thorac Oncol, V12, pe19, DOI 10.1016/j.jtho.2016.11.2217

← 1 2 3 4 5 6 7 8 9 10 →